key: cord-1056417-tvmcj144
authors: Macedo, Ana Cristina Lacerda; Prestes, Gabriele da Silveira; Colonetti, Tamy; Candido, Ana Claudia Rodrigues; Uggioni, Maria Laura Rodrigues; Gomes, Ariane Cruz; Silva, Fábio Rosa; Ceretta, Luciane Bisognin; Grande, Antonio José; da Rosa, Maria Inês
title: A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE ACCURACY OF SARS-COV-2 IGM AND IGG TESTS IN INDIVIDUALS WITH COVID-19
date: 2022-02-23
journal: J Clin Virol
DOI: 10.1016/j.jcv.2022.105121
sha: bb254ffbef3a61da67afe20949afc9e0a3231227
doc_id: 1056417
cord_uid: tvmcj144

INTRODUCTION: : Active SARS-CoV-2 infection is confirmed mainly through the detection of viral nucleic acid via the reverse transcriptase polymerase chain reaction (RT-PCR) technique. Methods to assess humoral responses contribute to the monitoring of the disease and confirmation of exposure to the virus. OBJECTIVE: : To evaluate the accuracy of tests for IgM and IgG antibodies for SARS-CoV-2 infection confirmed by RT-PCR and utility as complementary data for immunosurveillance. METHODS: : Literature research was performed by searching the terms “COVID-19”, “COVID-19 diagnostic testing” and “test” in the databases MEDLINE, EMBASE, Cochrane Library, Web of Science and Cumulative Index to Nursing and Allied Health Literature to search for potentially eligible observational studies without language restrictions published up to September 2020. RESULTS: : The pooled sensitivity and specificity, regardless of collection moment, was 80,0% (CI 95% 72.0-86.0) and 97.0% (CI 95% 94.0-98.0) for “IgM and/or IgG”, respectively. Serology considering immunoglobulins M and G together had a high accuracy performance on “fifteenth day and after”: sensitivity and specificity was 91.0% (CI 95% 85.0-94.0) and 98.0% (CI 95% 95.0-99.0) respectively, DOR 461 and AUC 0.98. CONCLUSION: : This study shows that serology is a group of tests with high accuracy, mainly following the second week after infection.

In December 2019, a new variety of coronaviruses, officially called Severe 87 Acute Respiratory Syndrome by Coronavirus-2 (SARS-CoV-2) was identified through 88 three patients who had atypical pneumonia in Wuhan, China [1, 2] . The rapid spread and 89 sustained transmission of the virus, gave rise to a pandemic within three months of 90 identification of the virus [3] . Worldwide, SARS-Cov-2 has infected more than 146 91 billion people, with more than 3 billion deaths (data obtained on April, 25, 2021) [4] . 92

Due to the overlap of manifestations, clinical diagnosis is problematic, especially during 93 seasonal flu [3] . 94

CoV-2 nucleic acid via the reverse transcriptase polymerase chain reaction (RT-PCR) 96

technique [3] . However, this test can only detect active infection and has variable 97 accuracy through the course of infection and therefore does not provide a complete 98 picture of the dynamics of infection. Additionally, RT-PCRs requires laboratories with 99 specific equipment and highly trained technicians to perform the test [5] . Moreover, this 100 technique requires the presence of sufficient quantities of the viral genome at the sample 101 reviewers were resolved by a third reviewer (TC) . 164 165

Data from all studies was independently extracted by two reviewers (ACM, 167 GSP) , and combined to construct a definitive dataset. Data was extracted from pre-168 piloted data extraction tables for study characteristics and placed on a 2x2 table for 169 study results. However, when this was not possible, corresponding authors were 170 contacted in order to obtain this data. 57 studies were excluded after further scrutiny: 9 studies included only confirmed cases, 192 31 were different design or editorial, 17 did not have serology and 1 did not have data 193 for extraction. We included a total of 45 studies in the review (Li et al., 2020 [4] , Guo et 194 al., 2020[5], Jin et al., 20207[7] , Adams et al., 2020 [12] , [13], 195 Algaissi et al., 2020 , [15], Benavid et al., 2020 [16], Cassaniti 196 et al., 2020 , Chan et al., 2020 [18], Charlton et al., 2020 , 197 [20], Freeman et al., 2020 , [22], Halsemann et al., 2020 198 [23], Harb et al., 2020 [24], Herroelen et al., 2020 , Jia et al. 2020 [26] , Lassauniere 199 et al., 2020 [27] , Lin et al. 2020 [28] , [29], Liu et al., 2020 (B) [30], 200 Liu et al., 2020 (C) [31], Long et al., 2020 [32] , Marinis et al., 2020[33] , Naaber et al., 201 2020 [34] , Pan et al., 2020 [35], Pancrazzi et al., 2020 [36], Paiva et al., 2020 [37], 202 Paradiso et al., 2020 [38], Pegoraro et al., 2020 [39], Perera et al., 2020 , Perez-203 Garcia et al., 2020 [41] , Pfluger et al., 2020 [42] , Pieri et al., 2020 [43] , Phipps et al., 204 2020 [44] , Suhandynata et al., 2020 [45] , [46], Tehrani et al., 2020 [47], 205 Turbett et al., 2020 , Vásárhelyi et al., 2020 [49] , [50], Yassine et 206 al., 2020 [51], Zhao et al., 2020 [52], Zhang et al., 2020 , Zhong et al., 2020[54] ). A 207 complete list of excluded studies is available upon request. 208 

Fourty-five primary studies were included in the analyses. A total of 13,650 213 patients met the inclusion criteria and were analyzed, including suspected cases, 214 confirmed cases and healthy volunteers. The main characteristics of the included studies 215 and samples are shown in Table 1 . Table 2 shows the sum contingency table and  216 analysis. 217 218 Quality assessment 219 QUADAS-2 was performed considering the following categories: selection of 220 patients, index and reference test, flow and timing ( Figure 2 ). Regarding selection, three 221 studies was considered "unclear" [15, 16, 54] . Regarding index fourteen studies were 222 considered "unclear" [12, 14, 15, 19, 20, 21, 22, 24, 43, 46, 47, 48, 51, 54] , since these 223 studies did not described blinding of workers involved in test collection and analyses, 224 but it was considered as a source of "low concern". Regarding the reference tests, all 225 studies received the same evaluation; limitations of PCR as a reference test are 226 mentioned in the discussion. Regarding flow and timing, twenty-two studies performed 227 "unclear" [7, 12, 13, 15, 21, 22, 23, 24, 25, 27, 32, 33, 34, 40, 41, 42, 44, 46, 47, 48, 51, 228 54] because did not show enough information about intervals between tests. , 38, 39, 41, 42, 43, 49] ; China was the origin of fifteen studies [4, 5, 7, 26, 28 , 29, 238 30, 31, 32, 35, 40, 50, 52, 53, 54] , two of these from Hong Kong [35, 40] ; there were 239 nine studies from USA (United States of America) [16, 18, 21, 24, 37, 44, 45, 47, 48] [4, 12, 16, 17, 18, 19, 22, 33, 37, 38, 47, 48, 49] 

Twenty-three studies applied Enzyme-Linked Immunosorbent Assay (ELISA), using 244 recombinant nucleocapsid protein-based (rN) and recombinant S polypeptide-based kit 245 (rS) [5, 12, 13, 14, 19, 21, 23, 25, 27, 28, 29, 31, 34, 39, 40, 42, 43, 46, 47, 50, 51, 52, 54] . Fifteen 246 used chemiluminescence immunoassay (MCLIA) [7, 23, 24, 25, 28, 32, 34, 37, 39, 42, 247 43, 44, 45, 46, 54] , by different manufactures, and eight used Colloidal gold-based 248 immunochromatographic (ICG) strip assay [41, 25, 26, 30, 35, 39, 50, 53] .

Results were discriminated, as shown in primary studies, by immunoglobulin 252 ("IgM" and "IgG" separately and "IgM, IgG or both" reactivity) but some kits only 253 tested both subclasses together ("IgM, IgG or both"). The pooled sensitivity and 254 specificity, regardless of collection moment, was 80,0% (95% CI 72.0-86.0) and 97.0% 255 (95% CI 94.0-98.0) for IgM and/or IgG, respectively. Serology considering 256 immunoglobulins M and G together had a high accuracy performance, as a DOR 257 (Diagnostic Odds Ratio) 131 and AUC (Area Under the Curve) 0.96. NPV on this 258 sample was 90.1% (95% CI 89.5 -90.7) and PPV, 84.5% (95% CI 83.3 -85.7). This 259 data and additional ones are described in Table2. 260 manufacturer, sample selection, and mainly by period of blood collection, considering 264 the number of days since the first symptoms. However, analysis by brand was not 265 possible since primary studies were done using a variety of them. 266

These analyses are explained on Table 2 . A comparison of the techniques 267 employed was not possible since most primary studies did not report results from more 268 than one test applied to the same sample results shown on table 2 must be considered in primary studies that used these tolls the sample was not whole blood, as in practice, 284 but serum or plasma. 285

An important find was the subanalyses by "characteristics of patients included". 286

Mostly studies included only "suspected cases", a cohort that configures a diagnostic 287 scenario, and "confirmed cases + pre-COVID samples, or healthy volunteers (PCR 288 tested or not)", characterizing a theorical scenario with "true positives" and "true 289 negatives" considering clinical feature. The AUC rised from 0.89 in "suspected cases" 290 to 0.99 in "confirmed cases + pre-COVID samples". It suggests that well-established 291 clinical criteria screening will improve tests performance. Complete analysis shown on 292

For the main analyses, including all techniques, I 2 was substantial heterogeneity in 298 sensitivity and specificity was found among studies in most analyses. In the Main 299 analysis, "IgM, IgG or both all techniques pooled", I 2 was 96.56 ( interventions [55] . 325 Hashem AM. SARS-CoV-2 S1 and N-based serological assays reveal rapid 467 seroconversion and induction of specific antibody response in COVID-19 patients. 468

Scientific reports. 10 (2020) 1-10, https://doi.org/10.1038/s41598-020-73491-5. with COVID-19. Nature Medicine. 26 (2020) 

SARS-CoV-2 infection serology validation of different methods: usefulness of IgA in 604 the early phase of infection

SARS-CoV-2 antibody responses do not predict COVID-19 disease 609 severity

Longitudinal Monitoring of SARS-CoV-2 IgM and IgG Seropositivity to Detect

surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike 618 protein-protein interaction

Detection of serum IgM and IgG for COVID-19

Developing antibody tests for SARS-CoV-2. The Lancet

SARS-COV-2 specific antibody 661 responses in COVID-19 patients

The Role of

Antibody Testing for SARS-CoV-2: Is There One

Temporal profiles 669 of viral load in posterior oropharyngeal saliva samples and serum antibody responses 670 during infection by SARS-CoV-2: an observational cohort study. The Lancet Infectious SARS-CoV-2

Diagnostic accuracy of serological 683 tests for covid-19: systematic review and meta-analysis

Advice on the use of point-of-care immunodiagnostic tests for COVID-19

INCLUDED STUDIES: ALL STUDIES -IgM and/or IgG

IgM only

DISCRIMINATED BY COLLECT PERIOD -Around 0-6th day

OF PATIENTS INCLUDED -Confirmed cases + pre-COVID samples OR healthy volunteers

Legend: FLQI: lateral flow qualitative immunoassay; ELISA rN: enzyme-linked immunosorbent assay recombinant nucleocapsid protein-based